Before concluding his discussion on the management of B-cell malignancies, an expert shares insight on the ongoing challenges in this space.
Transcript
Michael A. Kolodziej, MD: So the biggest challenges I think that we will continue to face are that we have to make decisions based on incomplete data. As I said earlier, it is certainly true that our options are better than they used to be, but we still don’t know what the best option is. And we need to be sensitive to that when we’re counseling a patient about treatment options. I think we’re going to continue to be challenged by the cost. The cost is a huge issue: the cost to society, as well as the cost to the individual patient. And we have to come to grips with how we’re going to deal with that. And I’m not going to take a political stance on whether I like anything that the administration proposed or not, that doesn’t really make any difference. It’s just true that we’ve got to do something.
And then the last challenge I think is sometimes I get the impression that we fall into certain lanes because we have a target that we know works. And my friend, Peter Bach, MD, MAPP, has written extensively on this and I think he’s right. And Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, has actually said this too, that we need to take chances, we need some real discovery. We need to come to grips with the idea that we’re going to actually cure certain malignancies or we’re going to treat them as chronic diseases. Either one is OK as far as I’m concerned. Each one has its relative advantages, obviously.
That we have a good option and maybe a better option is almost unfathomable because for years we had no good options. But I think we’re going to have to start sorting that out because it affects a lot about what our patients expect. It affects a lot about how much we’re willing to spend for this stuff.
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More